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Introduction: Several new targeted agents with anti-angiogenic properties
have been developed recently, including vandetanib, sunitinib, sorafenib,
bevacizumab and others. Tumor development, progression, metastasis are
strongly linked to angiogenesis. Targeted agents like bevacizumab, a mono-
clonal antibody which targets VEGF, have been fully developed in several solid
tumors. These new agents strongly advocate that targeting angiogenesis is
one of the best approaches for cancer therapy.
Areas covered: Those agents that target additional pro-angiogenic intracellu-
lar signaling pathways beyond VEGF signaling have also the potential to con-
tribute to anticancer therapies. The authors present here nintedanib (BIBF
1120), a triple angiokinase inhibitor. It targets not only VEGFRs, but also
FGFR and PDGFR. All the available clinical information regarding Phase I -- II
trials and the toxicity and efficacy of BIBF 1120 both as single agent and in
combination with cytotoxic agents in non-small cell lung cancer (NSCLC) is
reviewed and discussed here.
Expert opinion: Up till now, Phase I and II trials with nintedanib showed an
improvement for survival of advanced NSCLC patients. Tolerability profile
seems to be acceptable in these clinical trials. However, Phase III trials are
mandatory to translate these findings into clinical practice. The research for
predictive biomarkers could improve the success of these anti-angiogenic
agents.
Keywords: anti-angiogenesis, BIBF 1120, nintedanib, non-small cell lung cancer,
vascular endothelial growth factor
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1. Introduction
The process of angiogenesis involves the growth of new blood vessels mediated by
the balance between pro-angiogenic and anti-angiogenic factors [1]. The process of
tumor angiogenesis with vessel formation is crucial for the proliferation and enlarge-
ment of metastasizing cancer cells [2,3]. Some studies have shown an association
between neovascularization and prognosis in various solid tumors [4,5]. Tumor vas-
culature shows a highly aberrant structure and function, characterized by dilated,
tortuous, poorly organized and highly permeable vessels. This intratumoral micro-
environment induces interstitial hypertension, hypoxia and acidosis, causing
increased VEGF levels. Subsequently, chemotherapeutic drugs could not reach
tumor cells and clinical effectiveness is impaired.
VEGF plays a role in both normal and cancerous cells by promoting endothelial
migration and proliferation necessary for angiogenesis. There are three types of
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receptors for VEGF: VEGFR-1, VEGFR-2 and VEGFR-3.
However, the biological effects of VEGF are mediated by
VEFGR1 and VEFGR3. Instead, VEFGR-2 is believed to
have a primary role in endothelial cell activation. VEGF is
expressed in most cancers including lung cancer [6]. Elevated
VEGF levels are associated with increased tumor aggres-
siveness and result in a poor prognosis [7]. The primary effect
of anti-angiogenic agents is the inhibition of the abnormal
blood vessel formation [8,9]. Although at present there are sev-
eral anti-angiogenic agents available based on the inhibition of
a single component of angiogenesis, as in the case of the anti-
body bevacizumab, the therapeutic results of these agents are
far from optimal. The efforts of researchers are actually
directed to a wide set of new agents, able to target multiple
pathways implicated in angiogenesis, such as platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF) and
VEGF (Figure 1) [1,10,11].
Several PDGF receptor tyrosine kinases (TKs PDFGR) are
expressed on endothelial cells and pericytes. They could con-
trol various cellular mechanisms, such as the vessel stability,
the survival of endothelial cells and pericytes-endothelial cell
contact [12,13]. The activation by ligands and signal transduc-
tion through PDGFR are associated with malignancy deve-
lopment by cell migration and proliferation and tumor
angiogenesis [14,15]. FGF signaling is mediated by its TK
receptors, FGF receptors (FGFRs). It is regulated by its com-
plex expression patterns and binding specificity of the FGF
ligands and receptor isoforms. FGF signaling contributes to
tissue homeostasis, tissue repair, angiogenesis and inflamma-
tion (Figure 2). Its deregulation can have significant conse-
quences in carcinogenesis. The activation of the FGF
receptor tyrosine kinase (FGFR TKs) promotes cell prolifera-
tion and survival as well as the stimulation of angiogene-
sis [16,17]. The VEGF ligand regulates vascular proliferation
functioning as an anti-apoptotic factor for the new vessels
formed and also regulate the permeability thereof [12]. The
tumor cells have the ability to escape the sustained inhibition
of VEGF by regulating pro-angiogenic factors such as PDGF
and FGF (Figure 3) [13,18-20]. A study has shown that tumor
cells that are under the sustained inhibition of VEGF signal-
ing may change VEGF to FGF production [20]. As a conse-
quence, the development of new drugs has great relevance to
block multiple pathways simultaneously. This review aims
to summarize the clinical advances of nintedanib, an anti-
angiogenic agent, which inhibits VEGFR, FGFR and
PDFGR and has already reached Phase III trial advancement
(Box 1).
2. New drugs designed to inhibit
angiogenesis
Nintedanib comes after the market availability of several anti-
angiogenic agents. The first commercially available drug with
anti-angiogenic properties was bevacizumab [21]. Some prop-
erties of nintedanib resemble those of the existing agents while
others differ thereof. Bevacizumab blocks the VEGF-A and is
currently approved in combination with standard chemother-
apy [22] for the treatment of metastatic colorectal cancer, lung
(non-small cell carcinoma (NSCLC)), glioblastoma multi-
forme and kidney and is also indicated in Europe, in combi-
nation with chemotherapy for treatment of patients with
metastatic colorectal carcinoma, lung (non-squamous), renal
and breast [22]. The most common toxicities observed with
bevacizumab-based therapy include hypertension, proteinuria,
bleeding, fistula formation and thrombotic events [22-24].
In patients with squamous NSCLC, a severe bleeding has
been described. These safety and toxicity concerns have also
been observed in other small molecules with anti-angiogenic
properties [23,25]. Sorafenib is a small molecule that inhibits
VEGFR-2, VEGFR-3, PDGFR-v Rafm1 viral murine leuke-
mia oncogene homolog 1 (RAF) and the stem cell factor
receptor (c-kit) [26,27]. Sorafenib, an oral agent, is approved
for treatment of renal cell carcinoma and hepatocellular
carcinoma (HCC) [28,29]. Two Phase III trials of first-line
chemotherapy (ESCAPE -- paclitaxel/carboplatin and NEXUS --
gemcitabine/cisplatin) alone or in combination with sorafenib
failed to demonstrate clinical benefit [30,31]. An incidence of
bleeding similar to those reported with bevacizumab was
described in patients with squamous histology. Sunitinib, a
drug similar to those mentioned above, is a small molecule
Box 1. Drug summary.
Drug name Nintedanib
Phase Phase I/II
Indication Non-small cell lung cancer
Pharmacology
description
VEGFR tyrosine kinase inhibitor
Route of
administration
Oral
Chemical structure
O
O
O
N
N
N
N
O
N
Chemical name: (Z)-methyl 3-((4-
(N-methyl-2-(4-methylpiperazin-1-yl)
acetamido)phenylamino)(phenyl)
methylene)-2-oxoindoline-6-carboxylate
Pivotal trial(s) [47-50]
Pharmaprojects -- copyright to Citeline Drug Intelligence (an Informa
business). Readers are referred to Pipeline (http://informa-pipeline.
citeline.com) and Citeline (http://informa.citeline.com).
C. Rolfo et al.
2 Expert Opin. Investig. Drugs (2013) 22(8)
Ex
pe
rt 
O
pi
n.
 In
ve
sti
g.
 D
ru
gs
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
94
.2
26
.7
.1
84
 o
n 
06
/2
3/
13
Fo
r p
er
so
na
l u
se
 o
nl
y.
that inhibits VEGFR, PDGFR, c-kit and fms-like tyrosine
kinase 3 (Flt-3) and has indications similar to sorafenib (meta-
static renal carcinoma, gastrointestinal stromal tumor (GIST)
and pancreatic neuroendocrine tumors (pNET) [32,33]. Studies
have suggested that Phase II single agent sunitinib has activity
in pretreated patients with NSCLC. The results of these studies
report that 11% (7/63) and 29% (18/63) of patients achieved
stabilization of their disease for > 8 weeks [34]. Another study
involved 47 patients given sunitinib continuously reported a
2% response rate (1/47) and 23% stable diseases (11/47) [35].
Finally, vandetanib and other small molecules by oral adminis-
tration inhibited EGFR TK, VEGFR and RET (rearranged
during transfection). Vandetanib has recently been approved
for the treatment of medullary thyroid cancer [36-38]. For lung
cancer patients, vandetanib alone or in combination with
other agents has been studied in various randomized trials,
including ZEST [39], Zeal [40], ZODIAC [41] and
ZEPHYR [42]. Vandetanib did not prolong overall survival
in any of these studies. For this reason, it was not approved
in the USA by the Food and Drug Administration (FDA) [43].
3. Nintedanib: preclinical findings
Nintedanib is a triple angiokinase oral inhibitor that blocks
the VEGFR-1, VEGFR-2 and VEGFR-3, FGFR-1, FGFR-2
and FGFR-3, PDGFR-a and b TKs (Figure 4). It also has
activity against sarcoma viral oncogene (c-src) and Flt-3 [44].
Nintedanib is not yet approved for any indications in the
USA or Europe. This molecule is considered an indolinone
derivative. It is believed that the activation of the adenosine-
5¢-triphosphate (ATP) binding site in the kinase domain of
these receptors results in the receptor dimerization and the
consequent block of the angiogenic signal [44,45].
In vitro studies have demonstrated the ability of nintedanib
to inhibit proliferation of HUVEC (human umbilical vein
endothelial cell) stimulated by VEGF. There are also additives
and inhibitory effects when combined with paclitaxel. In par-
allel, the fraction of cells undergoing apoptosis is increased
with this combination [46]. This association was also analyzed
in NSCLC cell lines H460. In vitro studies showed that there
was a greater inhibition when nintedanib was combined with
paclitaxel. In vivo studies with the NSCLC models have
revealed that combination of BIBF 1120 with docetaxel in
H460 xenografts has clear antitumor efficacy. Similar studies
with xenograft models have also demonstrated that the
combination of pemetrexed with nintedanib is possible and
effective [46].
4. Trials with nintedanib in NSCLC
4.1 Nintedanib as single agent
In a Phase I, Mross et al. treated 51 patients affected by
various advanced tumors with nintedanib dose escalation [47].
Twenty-five patients received nintedanib at the dose of
50 -- 450 mg once a day and 36 patients received nintedanib
at a dose of 150 -- 300 mg twice daily in 4-week cycles with a
week off. The most common side effects were mild or moder-
ate. G3 toxicity was observed with different frequency for nin-
tedanib once daily versus twice daily: irreversible liver enzyme
elevation (12% grade 3 and 4% grade 4 vs 0% grade 3 and
2.8% grade 4), elevation of aspartate aminotransferase
(AST) (grade 3, 8 vs 2.8%), elevated alanine aminotransferase
(ALT) (grade 3, 0 vs 5.6%), g-glutamyl elevation transpepti-
dase (grade 3, 4 vs 5.6%), CD4 lymphocytes decrease (grade
A
B
C
Figure 1. Development of tumor vascularure. A. Tumor cells
produce pro-angiogenic factors which stimulate near blood
vessel for angiogenesis. B. The formation of new blood
vessels within the tumor tissue leads to a chaotic and
disorganized vascular structure. C. Anti-angiogenic drugs
block the vascularization of the tumor tissue.
Nintedanib
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3, 16 vs 5.6%), hypertension (grade 3, 4 vs 0%), diarrhea
(grade 3, 0 vs 2.8%), nausea (grade 3, 0 vs 5.6%) and vomiting
(grade 3, 0 vs 2.8%).
The maximum tolerated dose (MTD) for both once- and
twice-daily dosing was 250 mg. Another Phase I study in
Japanese patients with advanced lung cancer found out for
nintedanib a MTD of 200 mg twice daily. Twenty patients
received twice-daily nintedanib at 150 mg (n = 3), 200 mg
(n = 12) or 250 mg (n = 6). All dose-limiting toxicities were
largely reversible elevations in liver enzymes. It reported stable
disease for more than two cycles of treatment in 76% of
patients (n = 16) [48].
Nintedanib has also been studied in Phase II trials in
patients with locally advanced or metastatic NSCLC. To be
included in this trial, patients needed to fail at least after
one or two lines of chemotherapy (including a platinum
scheme). Patients were randomly assigned to a dose of
150 or 250 mg of nintedanib with a mean time to progression
of 6.9 weeks and no significant difference between the two
study groups. Median survival was 22 weeks. Patients with
Eastern Cooperative Oncology Group (ECOG) PS 0 -- 1
(n = 56) had a half time to progression of 11.6 weeks and a
median survival of 37.7 weeks. Forty-six percent of patients
were able to stabilize their disease. The most common adverse
effects reported were: nausea (57.5%), diarrhea (47.9%),
vomiting (42.5%), anorexia (28.8%), abdominal pain
(13.7%) and reversible elevation of transaminase levels: serum
glutamic oxaloacetic transaminase (SGOT; 13.7%) and
serum glutamic-pyruvic transaminase (SGPT) (9.6%). It is
noteworthy that nintedanib continuous treatment was well
tolerated, with no difference between treatment groups. The
time to progression and objective response rate found in this
study supported the opportunity of further studies about
this drug.
4.2 Nintedanib in combination with cytotoxic agents
Nintedanib has been studied in combination with other
standard chemotherapeutic regimens, such as pemetrexed or
the carboplatin/paclitaxel combination. In a Phase I trial, nin-
tedanib was combined with pemetrexed to treat recurrent or
advanced NSCLC (including all histologies) cancer patients
who had previously received at least one line of platinum-
based therapy [49]. The aim of this study was to determine
the dose escalation safety and tolerability and MTD of the
combination of nintedanib with pemetrexed. Included
patients could not have received prior treatment with peme-
trexed. Twenty-six patients were recruited for the safety anal-
ysis. The nintedanib MTD was 200 mg twice daily, when
administered for 21 days in combination with the standard
dose of pemetrexed. Among the first group of seven patients,
26.9% experienced a dose-limiting toxicity (DLT). One
patient received 100 mg twice daily of nintedanib, another
patient received 150 mg twice daily, three patients received
200 mg twice daily (one in the original cohort patient dose
escalation and two patients in the extension phase) and two
patients received 250 mg twice daily. DLTs included elevated
liver enzymes (3.8%), elevated AST only (3.8%), elevated
ALT only (7.6%), gastrointestinal events such as vomiting
(3.8%), esophageal pain (3.8%) and nausea (3.8%), fatigue
(19.2%), confusion (3.8%) and anorexia (3.8%). Most DLTs
occurred during the first week. All patients experienced some
adverse effects during the study. Gastrointestinal problems
were seen in 84.6% of patients and most consisted of nausea,
vomiting, abdominal pain and diarrhea. Local reactions related
to drug delivery were also reported in 76.9% of patients, that is,
erythema. The most common side effects reported in order of
frequency were fatigue (65.4%), nausea (61.5%), anorexia
(53.8%), erythema skin (38.5%), diarrhea (34.6%) and vomit-
ing (34.6%). One patient among the 26 who were recruited
cell
Smooth muscle
FGF, PDGF
Endothelial
cell
Tumour
VEGF, FGF
Hypoxia
PDGF
Pericyte
Figure 3. Mechanisms of tumor-related neoangiogenesis.
Since hypoxia develops within the tumor, pro-angiogenic
factors are produced to stimulate endothelial cell prolifera-
tion and pericyte regulation of angiogenesis.
FGF: Fibroblast growth factor; PDGF: Platelet-derived growth factor.
Pericyte
PDGFR
PDGFR
FGFR
FGFR
VEGFR
Endothelial cell
Smooth muscle cell
Figure 2. Receptors involved in tumor-related neoangiogen-
esis. Endothelial cells express FGFR and VEGFR. Smooth
muscle cells express FGFR and PDGFRF. Pericytes express
PDGFR.
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and treated with 100 mg nintedanib twice daily showed a quick
complete response 44 days after beginning treatment. The
authors reported that the patient was still in treatment with
nintedanib single agent twice a day at the moment of publica-
tion and it had been continued for 3.5 years. Among the
26 patients treated in this group, 13 (50%) experienced stable
disease as best response and 8 patients had disease progression.
The median time to progression for the 26 patients treated was
approximately 5.4 months. In conclusion, continued treatment
with pemetrexed in combination with nintedanib was tolerable
with interesting efficacy results, the combination of pemetrexed
and nintedanib is a viable treatment option that requires
further research.
In another Phase I study, the combination of nintedanib
with carboplatin/paclitaxel was investigated. The primary
objectives were to determine the safety and tolerability and
nintedanib MTD in patients with untreated advanced
NSCLC and ECOG PS 0 -- 1 [50]. Patients with squamous
cell histology were eligible for this study, but patients with
cavitary lesions or necrotic tumors or evidence that the mass
was near a major blood vessel were excluded. The study
involved a dose escalation of nintedanib (starting at 50 mg
twice daily) on days 2 -- 21 of each cycle combined with car-
boplatin (area under the curve (AUC) = 6) and paclitaxel
(200 mg/m2) on day 1 of each 21 days cycle. Patients were
treated for a minimum of four to a maximum of six cycles
of combination chemotherapy with the option to continue
with nintedanib in monotherapy after completion of
combination therapy. Nintedanib dose was escalated from
50 mg per cohort until the MTD was determined. The
MTD was defined as the dose of nintedanib to which
2 or > 6 in the cohort patients experienced DLT during
the first treatment cycle. The measurement of tumor lesions
was made at baseline and after every second cycle according
to RECIST criteria. Twenty-five patients were included and
14 were treated at the MTD in this study. The nintedanib
MTD was 200 mg twice daily in combination regimen
with carboplatin/ paclitaxel. This triple combination was
well tolerated. Five patients experienced DLT during the
first treatment cycle including transaminases increase
(2/5), thrombocytopenia (1/5), abdominal pain (1/5) and
redness (1/5); these toxicities resolved after the drug
was discontinued.
Ten patients received nintedanib as single agent after com-
pletion of the planned combination including two, three or
up to six cycles. According to RECIST criteria, considering
that 17 patients were eligible for response, 7 had partial
response and 10 patients had stable disease. Initial signs of
clinical efficacy were observed in patients who were in this
trial.
5. Expert opinion
Several agents such as nintedanib have been developed to
target angiogenesis or TKs. Some of them demonstrated
clinical utility as single agent or in combination with conven-
tional cytotoxic chemotherapy. The advantages of the drugs
belonging to this class are both the opportunity of oral admin-
istration and the availability of tools for targeting resistance in
the various pathways involved in cancer development and
progression. However, these advantages have not yet been
clearly translated into clinical benefit. For example, vandeta-
nib is a TK inhibitor which has anti-angiogenic properties,
but randomized clinical trials showed no benefit when com-
pared with other TK inhibitors such as gefitinib. So there is
a need to recognize the fact that nintedanib and other drugs
could improve survival when combined with chemotherapy,
but Phase III trials are necessary to clarify this topic. However,
this new drug has shown its good tolerability profile even with
full-dose chemotherapy regimens. This issue is mandatory to
guarantee an optimal inclusion of this kind of targeted drug
in the overall treatment strategies for lung cancer. According
to the information available today, the toxicities of these
agents are apparently acceptable but the number of patients
treated in the Phase I and Phase II trials is still too small to
reach a meaningful conclusion regarding both efficacy and
safety. For this reason, Phase III trials could help for better
knowledge of the toxicity related to these agents in advanced
NSCLC patients. It is also important to highlight that in
squamous lung cancers, severe bleeding was reported as
observed for bevacizumab. For this reason, a particular warn-
ing is mandatory for future clinical trials with nintedanib,
PDGFR
BIBF 1120: Triple angiokinase inhibitor
FGFR VEGFR
Figure 4. BIBF 1120 targets. BIBF 1120 is a multi-target
tyrosine kinase inhibitor. It binds to the intracellular tyrosine
kinase domain of angiogenesis-related receptors, including
FGFR, PDGFR and VEGFR.
Nintedanib
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since those patients with squamous histology should be
excluded. Another limitation for full clinical application of
nintedanib as well as the other anti-angiogenic agents is rep-
resented by the lack of predictive biomarkers for response.
The identification of prognostic and predictive factors is
essential to choose the best treatment option for each patient
and avoid unnecessary toxicity. Various efforts have been
made for defining tailored therapy. Several biomarkers were
evaluated, as in the ECOG 4599 study for the approval of
bevacizumab. Similarly, the authors evaluated markers such
as ICAM (soluble intercellular adhesion molecule). So far,
the identification of biomarkers for anti-angiogenic agents
is being studied.
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